Coronavirus patients can recuperate inside three days with new neutralizer mixed drink: Expert

Antibody-based antibody therapy is considered a new lethal start against COVID-19. Drugs mixed with alcohol have found enough space in the world media since they were given to former US President Donald Trump and actually a miracle drug? As AIG-based AIG hospitals begin treating these patients, Chairman Dr D Nageshwar Reddy confirmed that questions were being asked about the treatment. Hyderabad: Monoclonal antibody treatment is considered to be the latest weapon in the fight against COVID-19. This mixed drug has been found in the international media since it was introduced by former US President Donald Trump and is it actually a miracle drug? As AIG-based AIG hospitals begin treating these patients, Chairman Dr D Nageshwar Reddy said more questions were being asked about the treatment. Dr. Reddy said the current evidence of antibodies is yet to be tested but clinical research revolving around peer-reviewed diaries including the New England Journal of Medicine gives us strength as it appears to reduce hospitalization or exceed 70%, recalling a dramatic decline in viral load. To this Dr. Reddy added that the situation and the choice of patience comes from the problem

"More than 65 patients, adult patients, with uncontrolled diabetes, cardiovascular patients, people under the same immune system as patients are fighting for this treatment. The condition should also be corrected when given within three to seven days," said Drs. Reddy, who became the leading Indian artist to receive a grant from Rudolf V. Schindler, said he did. This can be given to patients over the age of 55 in the event that they have heart-related problems such as high blood pressure. He also said that, within a week, this treatment could help patients become RT-PCR Negative. "Pregnant women should not be offered this type of treatment because we need more information about the patient's well-being. In addition, if this combination is administered to patients who need high oxygen or a little cool air, clinical outcomes can be very serious, '' explains Dr. Reddy. "It has allowed us to somehow understand how the Monoclonal Antibodies work. They bind the spike proteins of the infection (S1 and S2) and thus reduce their frequency. At AIG, we are making an important report when we look at its inefficiency and the two types of infections, ”said Dr Reddy.

This treatment is likely to cause abnormalities and that is why the misuse of these antibodies should be completely weak, he said. When controlled patients should remain firm in any event for three months before receiving the injection. Treatment costs: Perhaps the most important part of the treatment is the costly items, especially in middle-income countries like India, where the cost of treatment is about Rs 70,000. "Medical clinics and doctors must pay for these costs so that they can be used legally," thought Drs. Reddy.